Risk assessment in drug development for symptomatic indications: a framework for the prospective exclusion of unacceptable cardiovascular risk.
Brass
Eric P
EP
Department of Medicine, Section of Vascular Medicine, University of Colorado Health Sciences Center, Colorado Prevention Center, and National Jewish Medical and Research Center, Denver, 80203, USA.
Lewis
Roger J
RJ
Lipicky
Raymond
R
Murphy
James
J
Hiatt
William R
WR
D000465:Algorithms; D002317:Cardiovascular Agents / Q000494:pharmacology*; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D000077407:Cilostazol; D006801:Humans; D018570:Risk Assessment; D013777:Tetrazoles / Q000009:adverse effects / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000009:adverse effects / Q000627:therapeutic use
D002317:Cardiovascular Agents; D013777:Tetrazoles; D014665:Vasodilator Agents; D000077407:Cilostazol